Dasatinib–Blinatumomab for Ph-Positive ALL
Dasatinib–Blinatumomab for Ph-Positive ALL
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
Foà et al. (Oct. 22 issue)
1
report the use of dasatinib and blinatumomab as first-line treatments in adults with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). This chemotherapy-free approach could be a breakthrough treatment for this condition, with fewer toxic adverse effects than treatment with...
Alternative Titles
Full title
Dasatinib–Blinatumomab for Ph-Positive ALL
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2481872297
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2481872297
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc2033785
